Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label extension study of HSK39297 for primary IgA nephropathy
CTR20253056Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ciprocopan in IgA nephropathy (IgAN), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
ciprocopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20253056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253056.